The ERC PoC focused on the exploitation of the technical viability of CryoDES in order to leverage the TRL level of the technology towards TRL 5, validation in relevant environment. To achieve this, several contacts with industrial partners were done and four main collaboration protocols were established. The work carried out targeted not only the development of CryoDES as cryoprotectant for stem cells with human therapeutic potential but also cell for veterinary applications.
- Grants and Subsidies
- Collaboration
- Business Angels
Partners to further validate our product.
Partner that can fund the research needed to go to market.
- Public or private funding institutions
- Research and Technology Organisations
- Private Investors
In order to ensure further uptake by the market, particularly the veterinary stem cell market, further research in different cells should be pursued. Additionally, an in depth market research should be carried out with this market segment. In parallel, the scaling-up and regulatory aspects related to the commercialization of the cryoprotectant agent should be assessed.
Result submitted to Horizon Results Platform by:
Universidade Nova de Lisboa, Portugal
